Navigation Links
AccessClosure Signs Distribution Agreement to Enter Into UK, Switzerland and France
Date:5/17/2011

MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- AccessClosure, Inc., the market segment leader in extravascular closure devices, announced today an exclusive agreement with Biosensors International  for the distribution of the Mynx™ Vascular Closure Device throughout the United Kingdom, Switzerland and France. The extravascular Mynx device, designed for patient comfort while providing hemostasis without sutures or implants, will be sold as part of Biosensors' interventional cardiology product range.

"These European countries represent a meaningful market opportunity for us, and we are pleased to be able to partner with Biosensors' established sales force for the distribution of Mynx," said Gregory D. Casciaro, President and CEO of AccessClosure. "Distribution in international markets is a key component of AccessClosure's growth strategy, and provides an excellent complement to our direct sales presence in the United States."

Biosensors will join AccessClosure's existing and growing global network of distributors.  Biosensors is now the fifth largest drug-eluting stent (DES) supplier globally, marketing  its BioMatrix™ family of DES systems which offer the unique combination of Biolimus A9™, an anti-restenotic drug developed by Biosensors exclusively for use with DES, and an abluminally-coated biodegradable polymer. Biosensors has a well established direct presence in the UK, Switzerland and France, and will provide AccessClosure with broad and rapid access to those markets.

"We are pleased to offer the Mynx device as part of our interventional cardiology product range" said Jeffrey B. Jump, CEO of Biosensors. "The Mynx device, paired with our portfolio of drug-eluting and bare-metal stents, allows us to offer a more complete solution to our customers. The Mynx has had great success in the United States and other international markets, and we anticipate similar success in these European countries."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to immediately seal the femoral artery. Dissolving within 30 days, Mynx leaves nothing behind but a healed artery. The extravascular device is designed for increased patient comfort and clinical versatility. The Mynx, which received its first FDA approval in May 2007, has been used in over 800,000 procedures to date.

About AccessClosure, Inc.

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience. For more information, please visit our website at http://www.accessclosure.com/

About Biosensors International

Biosensors International develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. With the increasing use of the BioMatrix™ family of drug-eluting stent systems, we are rapidly emerging as a leader in the global coronary stent market. For more information, please visit www.biosensors.com .


'/>"/>
SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
2. AccessClosure Announces Distribution Agreement for Radial Compression Band
3. Governor Daniels Signs Into Law Electronic Tracking Bill
4. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
5. Major Medical Diagnostics Manufacturer Signs Agreement to Use AmbiCom Wireless Solution in Its Urinalysis Product Line
6. Digital Assent Signs 100th PatientPad® Customer
7. Sysmex America Signs Distributorship Agreement With LABSCO
8. MedicaMetrix Signs Letter of Intent to Use Vytex® Natural Rubber Latex as Material of Choice in ProstaGlove™
9. Medical Care Technologies Inc. Signs Letter of Intent for Joint Venture in China
10. InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market
11. More Dangerous Than Drunk Driving, Hope Paige Designs Promotes a THUMBAND for Safe Texting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... disease and heart failure, today announced that it intends to ... stock in an underwritten public offering.  The offering is subject ... assurance as to whether or when the offering may be ... the offering.   --> --> ...
(Date:2/9/2016)... The global prefilled syringes market accounted for $3,905.1 million ... with a CAGR of 12.9% during 2015-2020. Among the ... global prefilled syringes market, with 90.1% share in 2014. ... global market of prefilled syringes is up surging with ... demand for vaccines, increasing prevalence of chronic and lifestyle ...
Breaking Medicine Technology:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional ... ensures the integrity of biological samples while operating at ultra-high pressures of 20,000 ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost ... Part D a decade ago, according to The Senior Citizens League (TSCL). ... they are coping with rapidly rising costs. “The implications are chilling, particularly for ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian Injury is ... may be one of many possible sources: sports, car accidents, falls, work accidents, ... Mastering Rehab Solutions for the Complexities of Concussions is designed for ...
Breaking Medicine News(10 mins):